Penbrook Management LLC acquired a new stake in shares of Becton Dickinson and Co (NYSE:BDX) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 4,150 shares of the medical instruments supplier’s stock, valued at approximately $888,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of BDX. Renaissance Technologies LLC raised its stake in shares of Becton Dickinson and by 1,192.1% during the fourth quarter. Renaissance Technologies LLC now owns 2,074,503 shares of the medical instruments supplier’s stock valued at $444,068,000 after purchasing an additional 1,913,952 shares during the period. BlackRock Inc. raised its stake in shares of Becton Dickinson and by 6.0% during the fourth quarter. BlackRock Inc. now owns 18,811,302 shares of the medical instruments supplier’s stock valued at $4,026,750,000 after purchasing an additional 1,071,288 shares during the period. Amundi Pioneer Asset Management Inc. raised its stake in shares of Becton Dickinson and by 332.3% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 559,551 shares of the medical instruments supplier’s stock valued at $119,776,000 after purchasing an additional 430,127 shares during the period. Atlantic Trust Group LLC raised its stake in shares of Becton Dickinson and by 597.3% during the third quarter. Atlantic Trust Group LLC now owns 451,035 shares of the medical instruments supplier’s stock valued at $88,381,000 after purchasing an additional 386,349 shares during the period. Finally, DSM Capital Partners LLC purchased a new stake in shares of Becton Dickinson and during the third quarter valued at approximately $75,155,000. Institutional investors own 83.35% of the company’s stock.

How to Become a New Pot Stock Millionaire

A number of analysts have recently issued reports on the stock. BMO Capital Markets assumed coverage on shares of Becton Dickinson and in a research note on Monday, March 5th. They set a “market perform” rating and a $249.00 price objective on the stock. Zacks Investment Research raised shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $259.00 price target for the company in a research report on Friday, January 19th. Bank of America reissued a “buy” rating and set a $260.00 price target on shares of Becton Dickinson and in a research report on Friday, January 19th. Morgan Stanley raised their price target on shares of Becton Dickinson and from $245.00 to $250.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 7th. Finally, Piper Jaffray Companies reissued an “overweight” rating and set a $260.00 price target (up previously from $223.00) on shares of Becton Dickinson and in a research report on Tuesday, February 6th. Six analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $238.00.

Shares of Becton Dickinson and stock opened at $218.38 on Thursday. The firm has a market cap of $58,546.72, a P/E ratio of 166.79, a PEG ratio of 1.60 and a beta of 1.18. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.93 and a current ratio of 1.54. Becton Dickinson and Co has a 1 year low of $175.66 and a 1 year high of $248.39.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $2.48 EPS for the quarter, topping analysts’ consensus estimates of $2.41 by $0.07. The firm had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The firm’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.33 earnings per share. research analysts expect that Becton Dickinson and Co will post 10.94 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 30th. Shareholders of record on Friday, March 9th will be issued a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a yield of 1.37%. The ex-dividend date is Thursday, March 8th. Becton Dickinson and’s dividend payout ratio is presently 229.01%.

In other Becton Dickinson and news, VP John E. Gallagher sold 5,346 shares of Becton Dickinson and stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $226.08, for a total value of $1,208,623.68. Following the completion of the transaction, the vice president now owns 9,391 shares of the company’s stock, valued at $2,123,117.28. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Thomas E. Polen, Jr. sold 1,877 shares of Becton Dickinson and stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $227.00, for a total transaction of $426,079.00. Following the completion of the transaction, the executive vice president now directly owns 15,387 shares of the company’s stock, valued at approximately $3,492,849. The disclosure for this sale can be found here. In the last ninety days, insiders sold 281,108 shares of company stock valued at $61,321,396. 1.00% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This piece was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.watchlistnews.com/penbrook-management-llc-acquires-shares-of-4150-becton-dickinson-and-co-bdx/1957738.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.